Scarica l'app Stockscreener
10.15
0.20%
0.02
Dopo l'orario di chiusura:
10.15
Precedente Chiudi:
$10.13
Aprire:
$10.125
Volume 24 ore:
977.25K
Relative Volume:
0.62
Capitalizzazione di mercato:
$388.48M
Reddito:
$127.70M
Utile/perdita netta:
$-121.25M
Rapporto P/E:
-3.2222
EPS:
-3.15
Flusso di cassa netto:
$-120.32M
1 W Prestazione:
-1.07%
1M Prestazione:
+0.59%
6M Prestazione:
+32.85%
1 anno Prestazione:
-38.15%
Intervallo 1D:
$10.12
$10.18
Intervallo di 1 settimana:
$10.10
$10.47
Portata 52W:
$4.80
$18.13
Iteos Therapeutics Inc Stock (ITOS) Company Profile
Nome
Iteos Therapeutics Inc
Settore
Industria
Telefono
857-204-4583
Indirizzo
321 ARSENAL STREET, WATERTOWN
Confronta ITOS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ITOS
Iteos Therapeutics Inc
|
10.15 | 387.33M | 127.70M | -121.25M | -120.32M | -3.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Iteos Therapeutics Inc Stock (ITOS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-28 | Downgrade | Wedbush | Outperform → Neutral |
| 2025-05-28 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-05-14 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-05-13 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-08-13 | Iniziato | Wells Fargo | Overweight |
| 2021-05-05 | Iniziato | H.C. Wainwright | Buy |
| 2020-10-08 | Iniziato | Robert W. Baird | Outperform |
| 2020-08-18 | Iniziato | JP Morgan | Overweight |
| 2020-08-18 | Iniziato | Piper Sandler | Overweight |
| 2020-08-18 | Iniziato | SVB Leerink | Outperform |
| 2020-08-18 | Iniziato | Wedbush | Outperform |
Mostra tutto
Iteos Therapeutics Inc Borsa (ITOS) Ultime notizie
SHAREHOLDER ALERT: Morris Kandinov Investigating AVDX, - GlobeNewswire
Is iTeos Therapeutics Inc. stock overhyped or has real potentialFree Predictions - jammulinksnews.com
What drives iTeos Therapeutics Inc. stock priceRapid growth opportunities - Autocar Professional
What analysts say about iTeos Therapeutics Inc. stockConsistent high-yield stocks - Autocar Professional
iTeos Therapeutics Inc. Stock Analysis and ForecastUnprecedented profits - Autocar Professional
Assessing the Fairness of iTeos Therapeutics' $10.047-per-Share Acquisition Offer: A Valuation Deep Dive - AInvest
ITEOS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iTeos Therapeutics, Inc.ITOS - The Globe and Mail
Is iTeos Therapeutics Inc. a good long term investmentHigh-profit trading signals - jammulinksnews.com
iTeos Therapeutics accepts takeover bid from Concentra - The Pharma Letter
Concentra buys beleaguered iTeos at slight discount - PharmaLive
iTeos Therapeutics stock price target lowered to $10 at Leerink Partners - Investing.com Canada
iTeos Therapeutics (NASDAQ:ITOS) Given Outperform Rating at Wedbush - Defense World
ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition of ITeos Therapeutics, Inc. - 富途牛牛
Securities Law Risks in Biotech M&A: A Closer Look at iTeos Therapeutics' Proposed Acquisition - AInvest
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and ZIMV on Behalf of Shareholders - GlobeNewswire Inc.
Rowley Law PLLC Investigates iTeos Therapeutics Acquisition for Securities Law Violations - AInvest
Navigating ITOS Stock: ITeos Therapeutics Inc Journey - investchronicle.com
iTeos Therapeutics To Be Acquired by Concentra Biosciences - citybiz
ITOS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of iTeos Therapeutics, Inc. Is Fair to Shareholders - The Globe and Mail
Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors - Stock Titan
Concentra To Acquire ITeos - Nasdaq
The Strategic Rationale and Valuation Implications of Concentra Biosciences' Acquisition of iTeos Therapeutics - AInvest
iTeos Therapeutics, Inc. Enters Merger Agreement with Concentra Biosciences, LLC for $10.047 per Share Acquisition - Quiver Quantitative
iTeos Therapeutics Enters into Agreement to Be Acquired by - GlobeNewswire
iTeos Announces 2025 Strategic Priorities and Anticipated Milestones - Informazione.it
What risks could impact iTeos Therapeutics Inc. stock performanceFree Stock Index Interpretation - Newser
Layoff Tracker: Following Challenges With DMD Therapy, Sarepta Will Cut 500 Employees - BioSpace
GSK and Iteos Therapeutics’ Promising Phase 3 Study on NSCLC Treatment - TipRanks
How iTeos Therapeutics Inc. stock performs during market volatilityFree Stock Market Expert Consultation - Newser
What makes iTeos Therapeutics Inc. stock price move sharplyStrategic High Profit Opportunities - Newser
Why iTeos Therapeutics Inc. stock attracts strong analyst attentionFree Stock Market Query - Newser
GSK and iTeos Therapeutics Advance Phase 3 NSCLC Study with Belrestotug and Dostarlimab - TipRanks
Iteos Therapeutics Inc Azioni (ITOS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):